NCT05380271View on ClinicalTrials.gov

Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2025

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG

sequential DEB-BACE and Arotinib and Tirelizumab

DEB-BACE+Arotinib + Tirelizumab

DRUG

DEB-BACE alone

DEB-BACE alone

All Listed Sponsors

lead

Gang Wu

OTHER